JP2020152729A5 - - Google Patents

Download PDF

Info

Publication number
JP2020152729A5
JP2020152729A5 JP2020104523A JP2020104523A JP2020152729A5 JP 2020152729 A5 JP2020152729 A5 JP 2020152729A5 JP 2020104523 A JP2020104523 A JP 2020104523A JP 2020104523 A JP2020104523 A JP 2020104523A JP 2020152729 A5 JP2020152729 A5 JP 2020152729A5
Authority
JP
Japan
Prior art keywords
human
seq
agent according
antibody
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020104523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020152729A (ja
Filing date
Publication date
Priority claimed from GB1322250.0A external-priority patent/GB2521355A/en
Priority claimed from GB1322253.4A external-priority patent/GB2521356B/en
Priority claimed from US14/138,446 external-priority patent/US8883157B1/en
Priority claimed from EP14172579.6A external-priority patent/EP2886558A1/en
Priority claimed from US14/331,665 external-priority patent/US9023359B1/en
Priority claimed from US14/331,730 external-priority patent/US9914769B2/en
Priority claimed from US14/331,609 external-priority patent/US9051378B1/en
Priority claimed from US14/457,566 external-priority patent/US8945560B1/en
Priority claimed from US14/457,536 external-priority patent/US9017678B1/en
Priority claimed from US14/472,818 external-priority patent/US8980273B1/en
Priority claimed from US14/472,828 external-priority patent/US8986691B1/en
Priority claimed from US14/472,698 external-priority patent/US8986694B1/en
Priority claimed from US14/472,685 external-priority patent/US8992927B1/en
Priority claimed from EP14185297.0A external-priority patent/EP2975058A1/en
Priority claimed from US14/500,233 external-priority patent/US9045548B1/en
Priority claimed from US14/507,368 external-priority patent/US9034332B1/en
Priority claimed from US14/536,049 external-priority patent/US9045545B1/en
Priority claimed from US14/537,403 external-priority patent/US9067998B1/en
Application filed filed Critical
Publication of JP2020152729A publication Critical patent/JP2020152729A/ja
Publication of JP2020152729A5 publication Critical patent/JP2020152729A5/ja
Priority to JP2021155708A priority Critical patent/JP7202431B2/ja
Pending legal-status Critical Current

Links

JP2020104523A 2013-12-17 2020-06-17 対象とするヒト標的に特異的に結合するリガンド Pending JP2020152729A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021155708A JP7202431B2 (ja) 2013-12-17 2021-09-24 対象とするヒト標的に特異的に結合するリガンド

Applications Claiming Priority (66)

Application Number Priority Date Filing Date Title
US201361916866P 2013-12-17 2013-12-17
US201361916862P 2013-12-17 2013-12-17
GB1322250.0 2013-12-17
US61/916,866 2013-12-17
US61/916,862 2013-12-17
GB1322250.0A GB2521355A (en) 2013-12-17 2013-12-17 Human targets I
GB1322253.4A GB2521356B (en) 2013-12-17 2013-12-17 Antibodies for use in treating conditions related to specific PCKS9 variants and associated diagnostic methods
GB1322253.4 2013-12-17
US14/138,446 US8883157B1 (en) 2013-12-17 2013-12-23 Targeting rare human PCSK9 variants for cholesterol treatment
US14/138,446 2013-12-23
US14/228,760 2014-03-28
US14/228,760 US8951523B1 (en) 2013-12-17 2014-03-28 Targeting rare human PCSK9 variants for cholesterol treatment
EP14172579.6A EP2886558A1 (en) 2013-12-17 2014-06-16 Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
EP14172579.6 2014-06-16
EP14172578.8A EP2886557A1 (en) 2013-12-17 2014-06-16 Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
EP14172578.8 2014-06-16
US14/331,609 2014-07-15
US14/331,609 US9051378B1 (en) 2014-07-15 2014-07-15 Targeting rare human PCSK9 variants for cholesterol treatment
US14/331,730 2014-07-15
US14/331,665 2014-07-15
US14/331,730 US9914769B2 (en) 2014-07-15 2014-07-15 Precision medicine for cholesterol treatment
US14/331,665 US9023359B1 (en) 2014-07-15 2014-07-15 Targeting rare human PCSK9 variants for cholesterol treatment
US14/457,566 2014-08-12
US14/457,536 2014-08-12
US14/457,536 US9017678B1 (en) 2014-07-15 2014-08-12 Method of treating rheumatoid arthritis using antibody to IL6R
US14/457,566 US8945560B1 (en) 2014-07-15 2014-08-12 Method of treating rheumatoid arthritis using antibody to IL6R
US14/472,818 2014-08-29
US14/472,818 US8980273B1 (en) 2014-07-15 2014-08-29 Method of treating atopic dermatitis or asthma using antibody to IL4RA
US14/472,685 2014-08-29
US14/472,685 US8992927B1 (en) 2014-07-15 2014-08-29 Targeting human NAV1.7 variants for treatment of pain
US14/472,698 2014-08-29
US14/472,828 US8986691B1 (en) 2014-07-15 2014-08-29 Method of treating atopic dermatitis or asthma using antibody to IL4RA
US14/472,828 2014-08-29
US14/472,698 US8986694B1 (en) 2014-07-15 2014-08-29 Targeting human nav1.7 variants for treatment of pain
US14/490,160 US8999341B1 (en) 2014-07-15 2014-09-18 Targeting rare human PCSK9 variants for cholesterol treatment
US14/490,175 2014-09-18
EP14185297.0 2014-09-18
US14/490,091 US9068012B1 (en) 2014-07-15 2014-09-18 Targeting rare human PCSK9 variants for cholesterol treatment
US14/490,160 2014-09-18
US14/490,175 US9040052B1 (en) 2013-12-17 2014-09-18 Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
EP14185297.0A EP2975058A1 (en) 2014-07-15 2014-09-18 Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
US14/490,112 US9034331B1 (en) 2014-07-15 2014-09-18 Targeting rare human PCSK9 variants for cholesterol treatment
US14/490,091 2014-09-18
US14/490,112 2014-09-18
US14/500,233 2014-09-29
US14/500,397 US10618971B2 (en) 2013-12-17 2014-09-29 Targeting rare human PCSK9 variants for cholesterol treatment
US14/500,397 2014-09-29
US14/500,233 US9045548B1 (en) 2014-07-15 2014-09-29 Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US14/507,368 2014-10-06
US14/507,368 US9034332B1 (en) 2014-07-15 2014-10-06 Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
EP14190945 2014-10-29
EP14190945.7 2014-10-29
US14/536,129 US9062105B1 (en) 2014-07-15 2014-11-07 Precision Medicine by targeting VEGF-A variants for treatment of retinopathy
US14/536,129 2014-11-07
US14/536,049 2014-11-07
US14/536,049 US9045545B1 (en) 2014-07-15 2014-11-07 Precision medicine by targeting PD-L1 variants for treatment of cancer
US14/537,403 US9067998B1 (en) 2014-07-15 2014-11-10 Targeting PD-1 variants for treatment of cancer
US14/537,403 2014-11-10
US14/552,816 US10611849B2 (en) 2013-12-17 2014-11-25 Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US14/552,816 2014-11-25
EP14196645.7 2014-12-05
EP14196641 2014-12-05
EP14196638.2 2014-12-05
EP14196641.6 2014-12-05
EP14196638 2014-12-05
EP14196645 2014-12-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016541434A Division JP6720079B2 (ja) 2013-12-17 2014-12-17 対象とするヒト標的に特異的に結合するリガンド

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021155708A Division JP7202431B2 (ja) 2013-12-17 2021-09-24 対象とするヒト標的に特異的に結合するリガンド

Publications (2)

Publication Number Publication Date
JP2020152729A JP2020152729A (ja) 2020-09-24
JP2020152729A5 true JP2020152729A5 (enrdf_load_stackoverflow) 2020-11-12

Family

ID=56800882

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016541434A Active JP6720079B2 (ja) 2013-12-17 2014-12-17 対象とするヒト標的に特異的に結合するリガンド
JP2020104523A Pending JP2020152729A (ja) 2013-12-17 2020-06-17 対象とするヒト標的に特異的に結合するリガンド
JP2021155708A Active JP7202431B2 (ja) 2013-12-17 2021-09-24 対象とするヒト標的に特異的に結合するリガンド

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016541434A Active JP6720079B2 (ja) 2013-12-17 2014-12-17 対象とするヒト標的に特異的に結合するリガンド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021155708A Active JP7202431B2 (ja) 2013-12-17 2021-09-24 対象とするヒト標的に特異的に結合するリガンド

Country Status (3)

Country Link
JP (3) JP6720079B2 (enrdf_load_stackoverflow)
CN (1) CN106062004A (enrdf_load_stackoverflow)
DE (2) DE112014005975T5 (enrdf_load_stackoverflow)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
EP3630840A1 (en) 2017-06-01 2020-04-08 Bristol-Myers Squibb Company Methods of treating a tumor using an anti-pd-1 antibody
CN108034712A (zh) * 2017-12-28 2018-05-15 上海市儿童医院 川崎病冠状动脉病变风险诊断与检测试剂盒
CN112088166A (zh) * 2018-03-26 2020-12-15 瑞泽恩制药公司 抗PfRH5抗体和其抗原结合片段
CN108315430B (zh) * 2018-04-28 2021-07-23 上海交通大学医学院附属仁济医院 Pdl1 snp基因型作为预测乳腺癌新辅助化疗疗效标记物的用途
GB201820687D0 (en) * 2018-12-19 2019-01-30 Kymab Ltd Antagonists
CN111487398B (zh) * 2019-01-25 2022-11-11 四川大学华西医院 血管瘤治疗的生物标记物
CN115243762A (zh) * 2020-04-07 2022-10-25 迈威(美国)生物治疗有限公司 抗tmprss6抗体及其用途
CN113804895A (zh) * 2020-06-17 2021-12-17 首都医科大学附属北京世纪坛医院 尿液免疫球蛋白重链可变区3-7及其多肽片段在烧伤中的应用
CN112941164A (zh) * 2021-01-27 2021-06-11 右江民族医学院附属医院 利用目标基因测序检测trpc6基因致病突变的方法
CN113502325B (zh) * 2021-07-02 2024-09-10 厦门市妇幼保健院(厦门市优生优育服务中心、厦门大学附属妇女儿童医院、厦门市林巧稚妇女儿童医院) 用于孕期铁营养缺乏风险评估检测试剂盒与应用方法
CN113945723B (zh) * 2021-10-28 2024-03-12 复旦大学附属中山医院 预测免疫检查点抑制剂治疗相关肺炎发生风险的系统、储存介质及其应用
WO2024253462A1 (ko) * 2023-06-07 2024-12-12 중앙대학교 산학협력단 스클레로스틴 억제제를 유효성분으로 포함하는 당뇨병성 안질환 예방 또는 치료용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
MX367075B (es) * 2011-01-28 2019-08-05 Sanofi Biotechnology Anticuerpos humanos frente a pcsk9 para su uso en metodos de tratamiento de grupos concretos de pacientes.
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
RS66342B1 (sr) * 2011-09-16 2025-01-31 Regeneron Pharma Metode za snižavanja nivoa lipoproteina administracijom inhibitora proproteinske konvertaze suptilizin/keksin tipa 9 (pcsk9)
AU2012311286B2 (en) * 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use

Similar Documents

Publication Publication Date Title
JP2020152729A5 (enrdf_load_stackoverflow)
CN107109494B (zh) Il-33介导型疾病的治疗方法和诊断方法
JP2008529536A5 (enrdf_load_stackoverflow)
RU2694980C2 (ru) Способы избирательного лечения астмы с использованием антагонистов il-13
JP2009515524A5 (enrdf_load_stackoverflow)
JP2003529315A (ja) 病気の診断および治療のための成分および方法
CN103865997B (zh) 高血压易感基因组的鉴定
KR20230156746A (ko) 궤양성 결장염에서 치료 반응을 예측하는 방법
US20040235006A1 (en) Chemical compounds
WO2001020031A2 (en) Polymorphisms in a klotho gene
US20040018493A1 (en) Haplotypes of the CD3E gene
Lee et al. Polymorphism in the serotonin transporter protein gene in Maltese dogs with degenerative mitral valve disease
EP1203827A2 (en) Polymorphisms in the human KDR gene
KR102003835B1 (ko) 섬유증 감수성 il22ra2 유전자 및 이의 용도
KR20140096073A (ko) 혈관신생 억제제에 대한 반응성
TW200401035A (en) The IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
JP4242590B2 (ja) 慢性関節リウマチの疾患感受性遺伝子、及びその利用
US20190082912A1 (en) Methods Of Selectively Treating Asthma Using IL-13 Antagonists
CN115976183B (zh) 预测干扰素α对乙型肝炎患者治疗疗效的分子标记及其应用
CN115976184B (zh) 用于预测干扰素α对乙型肝炎患者治疗疗效的分子标记及其应用
WO2000050436A1 (en) Receptor isogenes: polymorphisms in the tissue necrosis factor receptor
Lee ChangMin et al. Polymorphism in the serotonin transporter protein gene in Maltese dogs with degenerative mitral valve disease.
KR20240067064A (ko) 레티쿨로칼빈-3[rcn3] 변이체 및 인터류킨-4 수용체 알파[il4r] 길항제를 이용한 천식의 치료
JP4317376B2 (ja) 糖尿病性腎症遺伝子の検出方法
JP2003506074A (ja) 薬剤標的同質遺伝子：免疫グロブリンｅ受容体ｉａｌｐｈａサブユニット遺伝子における多型